Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.34 |
| ▸ | GPR88 | Q9GZN0 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | RARB | P10826 | 1/20 | 0.33 |
| ▸ | ACACB | O00763 | 1/20 | 0.33 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 7/20 | 0.33 |
| ▸ | S1PR5 | Q9H228 | 6/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.32 |
| ▸ | S1PR3 | Q99500 | 4/20 | 0.32 |
| ▸ | MEN1 | O00255 | 3/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3914447 | 0.98 | ACACB (0.35) | KDM4EGPR88TDP1SMN1; SMN2RARB | |
| SCHEMBL3912300 | 0.88 | KDM4E (0.30) | KDM4ESMN1; SMN2KMT2AALDH1A1 | |
| SCHEMBL1037741 | 0.87 | NPC1 (0.39) | KDM4ESMN1; SMN2KMT2AMEN1NPC1 | |
| SCHEMBL3905395 | 0.87 | PAX8 (0.36) | SMN1; SMN2KMT2AMEN1LMNAALDH1A1 | |
| SCHEMBL2682844 | 0.84 | GAA (0.41) | SMN1; SMN2ACACBKMT2AMEN1NPC1 | |
| SCHEMBL3948391 | 0.83 | REN (0.44) | — | |
| SCHEMBL2684607 | 0.82 | — | — | |
| SCHEMBL2684431 | 0.81 | TSHR (0.36) | KDM4ESMN1; SMN2KMT2AMEN1NPC1 | |
| SCHEMBL5281026 | 0.81 | TSHR (0.36) | KDM4ESMN1; SMN2KMT2AMEN1NPC1 | |
| SCHEMBL3912312 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325947-A1 | NITRATE ESTERS OF PIPERIDINES | NOVARTIS AG (CH) | 2009-12-31 | — | — | US | disclosed |
| EP-2049514-A1 | NITRATE ESTERS OF PIPERIDINES | Speedel Experimenta AG (CH) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008017685-A1 | NITRATE ESTERS OF PIPERIDINES | SPEEDEL EXPERIMENTA AG (CH) | 2008-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325947-A1 | NITRATE ESTERS OF PIPERIDINES | NOS2, NOS1, NOS3 | KDM4E 2131/4885GPR88 2486/4885TDP1 1420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.